Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | PDE3B | Q13370 | 2/20 | 0.33 |
| ▸ | PDE3A | Q14432 | 2/20 | 0.33 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.32 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.32 |
| ▸ | NAMPT | P43490 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28242885 | 0.85 | SIGMAR1 (0.35) | SIGMAR1PDE3BPDE3ACHRNB2CHRNA4 | |
| SCHEMBL28319871 | 0.74 | SIGMAR1 (0.32) | SIGMAR1PDE3BPDE3ACHRNB2CHRNA4 | |
| SCHEMBL28319875 | 0.74 | PDE3B (0.34) | SIGMAR1PDE3BPDE3ACHRNB2CHRNA4 | |
| SCHEMBL3818780 | 0.73 | NAMPT (0.35) | PDE3BPDE3ANAMPT | |
| SCHEMBL30385312 | 0.72 | HDAC3 (0.41) | — | |
| SCHEMBL1564351 | 0.72 | HDAC3 (0.41) | — | |
| SCHEMBL31691807 | 0.71 | HDAC2 (0.36) | PDE3BPDE3ANAMPT | |
| SCHEMBL28319864 | 0.71 | CA12 (0.35) | SIGMAR1PDE3BPDE3ANAMPT | |
| Iodide SCHEMBL4322466 | 0.71 | HDAC3 (0.40) | — | |
| Iodide SCHEMBL11870312 | 0.71 | HDAC3 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2997021-B1 | NEW SOMATOSTATIN RECEPTOR SUBTYPE 4 (SSTR4) AGONISTS | CENTREXION THERAPEUTICS CORP (US) | 2017-12-20 | — | — | EP | disclosed |
| EP-3141542-A1 | SUBSTITUTED BENZALDEHYDE COMPOUNDS AND METHODS FOR THEIR USE IN INCREASING TISSUE OXYGENATION | Global Blood Therapeutics, Inc. (US) | 2017-03-15 | — | — | EP | disclosed |